Company Overview and News

0
RattanIndia Power Limited - Financial Result Updates

2018-05-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTNPOWER 533122

4
Ashok Leyland, Bajaj Auto results

2018-05-17 thehindubusinessline
Close to 60 companies including Alphageo, Amara Raja, Ashok Leyland, Asian Granito, Bajaj Auto, Bajaj Holdings, Capacite, Dalmia Bharat, Den Networks, Future Lifestyle, Inox Wind, Kanoria Chem, Kirloskar Oil, Manappuram Finance, Mangalam Timber, Pennar Ind, Pennar Engineered, Prabhat Diary, Thermax, RattanIndia Infra, RattanIndia Power, Strides Shasun, Surya Roshini, Winsome Yarns and Union Bank will declare their quarter and full-year results for FY18.
BAJAJ-AUTO UBNC DALMIABHA WINSOME RTNPOWER 514348 533122 532977 AKLD 533137 531213 DEN 533309 INOXWIND MANAPPURAM 500477 539083 AKLS ASHOKLEY

0
RattanIndia Power Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTNPOWER 533122

0
RattanIndia Power Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTNPOWER 533122

0
RattanIndia Power Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTNPOWER 533122

2
Infra stocks see investor interest revival

2018-04-04 thehindubusinessline
Priya Kansara After a prolonged period of stepmotherly treatment towards infrastructure stocks for a plethora of reasons, sentiment towards them has been finally changing in a positive way. In other words, infrastructure stocks are again gaining investor interest after a long hiatus.
SUZLON 539150 532939 533271 533096 RTNPOWER GMRINFRA 532714 GMQRY ASHOKA PNCINFRA 532710 532754 JSWENERGY CMQMY ENGINERSIN BFUTILITIE CUMMINSIND 522287 SADBHAV KEC SUEL TWL RPOWER TATAPOWER PTC 533122 532966 532667 532524 533148 532178 500480 532430 TPCL KALPATPOWR 500400 ADANIPOWER

0
RattanIndia Power Limited - Change in Director(s)

2018-03-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTNPOWER 533122

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...